Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 21st January 2022
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Collaboration to discover canine therapeutic antibodies
"This strategic partnership is another example of our commitment to address unmet needs in the animal health market" - Stephen Martin, Boehringer Ingelheim Animal Health.

Boehringer Ingelheim and MabGenesis will combine their expertise to develop new products.   

Boehringer Ingelheim and biopharmaceutical firm MabGenesis are joining forces to discover new canine monoclonal antibodies for potential therapeutic treatments. 

The partnership will see MabGenesis apply its unique technology platform to discover first class antibodies against targets of interest selected by Boehringer Ingelheim. 

While the terms of the agreement have not been disclosed, Boehringer will have the right to develop and commercialise the resulting products for the veterinary market. 

Katsuhiro Shinjo, chief executive officer of MabGenesis, said: “We are excited to partner with global animal health leader Boehringer Ingelheim as we feel we bring complementary expertise to this collaboration. 

“The combination of our innovative discovery platform, MOURA Library and IMPACT, and Boehringer Ingelheim’s capability and industry leadership will surely lead to the discovery of innovative canine therapeutic antibodies bringing benefits to animal health.”

Boehringer Ingelheim said that strengthening partnership to accelerate innovation is key in its research and development strategy. 

Stephen Martin, head of research at Boehringer Ingelheim Animal Health, said: “We believe that collaboration and shared innovation can lead to groundbreaking solutions to better predict, prevent, detect and treat diseases.

"This strategic partnership is another example of our commitment to address unmet needs in the animal health market with the aim to improve the lives of animals and humans.”

Become a member or log in to add this story to your CPD history

Birmingham Dogs Home makes urgent appeal

News Story 1
 Birmingham Dogs Home has issued an urgent winter appeal as it faces more challenges over the Christmas period.

The rescue centre has seen a dramatic increase in dogs coming into its care, and is currently caring for over 200 dogs. With rising costs and dropping temperatures, the charity is calling for urgent support.

It costs the charity £6,000 per day to continue its work.

Fi Harrison, head of fundraising and communications, said: "It's heart-breaking for our team to see the conditions some dogs arrive in. We really are their last chance and hope of survival."

More information about the appeal can be found here. 

Click here for more...
News Shorts
Avian flu confirmed at premises in Cornwall

A case of highly pathogenic avian influenza H5N1 has been detected in commercial poultry at a premises near Rosudgeon, Cornwall.

All poultry on the infected site will be humanely culled, and a 3km protection zone and 10km surveillance zone have been put in place. Poultry and other captive birds in the 3km protection zone must be housed.

The case is the second avian flu case confirmed in commercial poultry this month. The H5N5 strain was detected in a premises near Hornsea, East Riding of Yorkshire, in early November. Before then, the disease had not been confirmed in captive birds in England since February.

The UK chief veterinary officer has urged bird keepers to remain alert and practise robust biosecurity.

A map of the disease control zones can be found here.